|
1
|
Nakhjavani M, Hardingham JE, Palethorpe
HM, Price TJ and Townsend AR: Druggable molecular targets for the
treatment of triple negative breast cancer. J Breast Cancer.
22:341–361. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malla RR, Kumari S, Gavara MM, Badana AK,
Gugalavath S, Kumar DK and Rokkam P: A perspective on the
diagnostics, prognostics, and therapeutics of microRNAs of
triple-negative breast cancer. Biophys Rev. 11:227–234. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He MY, Rancoule C, Rehailia-Blanchard A,
Espenel S, Trone JC, Bernichon E, Guillaume E, Vallard A and Magne
N: Radiotherapy in triple-negative breast cancer: Current situation
and upcoming strategies. Crit Rev Oncol Hematol. 131:96–101. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan Z, Guo GF and Zhang B: Research of
Brucea javanica against cancer. Chin J Integr Med.
23:153–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dou YX, Zhou JT, Wang TT, Huang YF, Chen
VP, Xie YL, Lin ZX, Gao JS, Su ZR and Zeng HF: Self-nanoemulsifying
drug delivery system of bruceine D: A new approach for
anti-ulcerative colitis. Int J Nanomedicine. 13:5887–5907. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lau ST, Lin ZX, Liao Y, Zhao M, Cheng CH
and Leung PS: Bruceine D induces apoptosis in pancreatic
adenocarcinoma cell line PANC-1 through the activation of
p38-mitogen activated protein kinase. Cancer Lett. 281:42–52. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lau ST, Lin ZX and Leung PS: Role of
reactive oxygen species in brucein D-mediated p38-mitogen-activated
protein kinase and nuclear factor-kappaB signalling pathways in
human pancreatic adenocarcinoma cells. Br J Cancer. 102:583–593.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu L, Lin ZX, Leung PS, Chen LH, Zhao M
and Liang J: Involvement of the mitochondrial pathway in bruceine
D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma
cells. Int J Mol Med. 30:93–99. 2012.PubMed/NCBI
|
|
10
|
Xiao Z, Ching Chow S, Han Li C, Chun Tang
S, Tsui SK, Lin Z and Chen Y: Role of microRNA-95 in the anticancer
activity of Brucein D in hepatocellular carcinoma. Eur J Pharmacol.
728:141–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Irani S: Emerging insights into the
biology of metastasis: A review article. Iran J Basic Med Sci.
22:833–847. 2019.PubMed/NCBI
|
|
12
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang H, Duan L, Zou Z, Li H, Yuan S, Chen
X, Zhang Y, Li X, Sun H, Zha H, et al: Activation of the
PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced
viability and migration in colorectal cancer cells. Int J Med Sci.
11:841–849. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Xu X, Li Y, Zou K, Zhang Z, Xu X,
Liao Y, Zhao X, Jiang W, Yu W, et al: Synergistic antitumor effect
of BKM120 with prima-1met via inhibiting PI3K/AKT/mTOR and
CPSF4/hTERT signaling and reactivating mutant P53. Cell Physiol
Biochem. 45:1772–1786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao G, Tian Y, Sun Z, Ou J and Xu H:
Bruceine D isolated from Brucea javanica (L.) merr. As a
systemic feeding deterrent for three major lepidopteran pests. J
Agric Food Chem. 67:4232–4239. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C,
Zu X, Yang N, Ke X, Zhou J, et al: Bruceine D inhibits
hepatocellular carcinoma growth by targeting β-catenin/jagged1
pathways. Cancer Lett. 403:195–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yap AS, Crampton MS and Hardin J: Making
and breaking contacts: The cellular biology of cadherin regulation.
Curr Opin Cell Biol. 19:508–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wells A, Yates C and Shepard CR:
E-cadherin as an indicator of mesenchymal to epithelial reverting
transitions during the metastatic seeding of disseminated
carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and
N-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8:E1182019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li B, Shi H, Wang F, Hong D, Lv W, Xie X
and Cheng X: Expression of E-, P- and N-cadherin and its clinical
significance in cervical squamous cell carcinoma and precancerous
lesions. PLoS One. 11:e01559102016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berx G and Van Roy F: The
E-cadherin/catenin complex: An important gatekeeper in breast
cancer tumorigenesis and malignant progression. Breast Cancer Res.
3:289–293. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Debies MT and Welch DR: Genetic basis of
human breast cancer metastasis. J Mammary Gland Biol Neoplasia.
6:441–451. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilmanns C, Grossmann J, Steinhauer S,
Manthey G, Weinhold B, Schmitt-Graff A and von Specht BU: Soluble
serum E-cadherin as a marker of tumour progression in colorectal
cancer patients. Clin Exp Metastasis. 21:75–78. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sloan EK and Anderson RL: Genes involved
in breast cancer metastasis to bone. Cell Mol Life Sci.
59:1491–1502. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scanlon CS, Van Tubergen EA, Inglehart RC
and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in
squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanaka K, Tokunaga E, Inoue Y, Yamashita
N, Saeki H, Okano S, Kitao H, Oki E, Oda Y and Maehara Y: Impact of
expression of vimentin and axl in breast cancer. Clin Breast
Cancer. 16:520–526.e2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu R, Zhou Z, Yu W, Xia Y and Zhi X: CPEB4
promotes cell migration and invasion via upregulating vimentin
expression in breast cancer. Biochem Biophys Res Commun.
489:135–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zelenko Z, Gallagher EJ, Tobin-Hess A,
Belardi V, Rostoker R, Blank J, Dina Y and LeRoith D: Silencing
vimentin expression decreases pulmonary metastases in a
pre-diabetic mouse model of mammary tumor progression. Oncogene.
36:1394–1403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Conacci-Sorrell M, Zhurinsky J and
Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and
cancer. J Clin Invest. 109:987–991. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ren L, Chen H, Song J, Chen X, Lin C,
Zhang X, Hou N, Pan J, Zhou Z, Wang L, et al: MiR-454-3p-mediated
Wnt/β-catenin signaling antagonists suppression promotes breast
cancer metastasis. Theranostics. 9:449–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan X, Lyu T, Jia N, Yu Y, Hua K and Feng
W: Huaier aqueous extract inhibits ovarian cancer cell motility via
the AKT/GSK3β/β-catenin pathway. PLoS One. 8:e637312013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Y, Liu C, Tan T, Li S, Tang S and Chen
X: Sinomenine sensitizes human gastric cancer cells to cisplatin
through negative regulation of PI3K/AKT/Wnt signaling pathway.
Anticancer Drugs. 30:983–990. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elmenier FM, Lasheen DS and Abouzid KA:
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to
combat cancer. Eur J Med Chem. 183:1117182019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ning J, Liu W, Zhang J, Lang Y and Xu S:
Ran GTPase induces EMT and enhances invasion in non-small cell lung
cancer cells through activation of PI3K-AKT pathway. Oncol Res.
21:67–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Xiao L, Luo CH, Zhou H, Hu J, Tang
YX, Fang KN and Zhang Y: Overexpression of TRPM7 is associated with
poor prognosis in human ovarian carcinoma. Asian Pac J Cancer Prev.
15:3955–3958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakanishi K, Sakamoto M, Yasuda J,
Takamura M, Fujita N, Tsuruo T, Todo S and Hirohashi S: Critical
involvement of the phosphatidylinositol 3-kinase/Akt pathway in
anchorage-independent growth and hematogeneous intrahepatic
metastasis of liver cancer. Cancer Res. 62:2971–2975.
2002.PubMed/NCBI
|
|
39
|
Lai ZQ, Ip SP, Liao HJ, Lu Z, Xie JH, Su
ZR, Chen YL, Xian YF, Leung PS and Lin ZX: Brucein D, a naturally
occurring tetracyclic triterpene quassinoid, induces apoptosis in
pancreatic cancer through ROS-associated PI3K/Akt signaling
pathway. Front Pharmacol. 8:9362017. View Article : Google Scholar : PubMed/NCBI
|
